mdl 100240 has been researched along with cyclic gmp in 1 studies
| Studies (mdl 100240) | Trials (mdl 100240) | Recent Studies (post-2010) (mdl 100240) | Studies (cyclic gmp) | Trials (cyclic gmp) | Recent Studies (post-2010) (cyclic gmp) |
|---|---|---|---|---|---|
| 21 | 9 | 0 | 22,346 | 333 | 4,062 |
| Protein | Taxonomy | mdl 100240 (IC50) | cyclic gmp (IC50) |
|---|---|---|---|
| Phosphodiesterase | Bos taurus (cattle) | 0.1 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 2.4 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 2.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biollaz, J; Brunner, HR; Brunner-Ferber, F; Buclin, T; Décosterd, LA; La Roche, SD; Nussberger, J; Rousso, P | 1 |
1 trial(s) available for mdl 100240 and cyclic gmp
| Article | Year |
|---|---|
Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Benzazepines; Blood Pressure; Cross-Over Studies; Cyclic GMP; Diet, Sodium-Restricted; Endocrine System; Follow-Up Studies; Humans; Infusions, Intravenous; Kidney; Male; Neprilysin; Peptidyl-Dipeptidase A; Posture; Pyridines; Reference Values; Renal Plasma Flow, Effective; Safety; Stereoisomerism | 1999 |